[
  {
    "ts": null,
    "headline": "Robert Bruce's Strategic Moves in Q3 2024: Spotlight on AerCap Holdings NV",
    "summary": "Insight into the Investment Shifts of Bruce & Co",
    "url": "https://finnhub.io/api/news?id=0863edfe70e3f51fad1480fc821b354f0dbfc2567a9a6d73bfb15e3c647e25b2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731624986,
      "headline": "Robert Bruce's Strategic Moves in Q3 2024: Spotlight on AerCap Holdings NV",
      "id": 131362068,
      "image": "https://s.yimg.com/ny/api/res/1.2/MCx5mlavze6PQIDpz6_mig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD04NzE-/https://media.zenfs.com/en/us.finance.gurufocus/6ba4e4c461601cc4a7cdb761cbc5f3df",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "Insight into the Investment Shifts of Bruce & Co",
      "url": "https://finnhub.io/api/news?id=0863edfe70e3f51fad1480fc821b354f0dbfc2567a9a6d73bfb15e3c647e25b2"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Inc. stock outperforms competitors despite losses on the day",
    "summary": "AbbVie Inc. stock outperforms competitors despite losses on the day",
    "url": "https://finnhub.io/api/news?id=335b0a8a81d43492c36f717d6077ad1c37cded7c4e19d5e797085a5b39ad1025",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731602100,
      "headline": "AbbVie Inc. stock outperforms competitors despite losses on the day",
      "id": 131414139,
      "image": "",
      "related": "ABBV",
      "source": "MarketWatch",
      "summary": "AbbVie Inc. stock outperforms competitors despite losses on the day",
      "url": "https://finnhub.io/api/news?id=335b0a8a81d43492c36f717d6077ad1c37cded7c4e19d5e797085a5b39ad1025"
    }
  },
  {
    "ts": null,
    "headline": "Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal",
    "summary": "SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.",
    "url": "https://finnhub.io/api/news?id=9ff15fb98645c3acd3038c96b95ca2c77c204a7202b4c5ebce9ec59b9061a240",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731597840,
      "headline": "Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary Goal",
      "id": 131356405,
      "image": "https://media.zenfs.com/en/zacks.com/17664ed95646b97db9beb170298a16b3",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "SYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.",
      "url": "https://finnhub.io/api/news?id=9ff15fb98645c3acd3038c96b95ca2c77c204a7202b4c5ebce9ec59b9061a240"
    }
  },
  {
    "ts": null,
    "headline": "2 Dividend Stocks to Buy Hand Over Fist in November",
    "summary": "These companies have solid businesses and excellent dividend growth track records.",
    "url": "https://finnhub.io/api/news?id=2f826d3cfb75dfab1f1d576691ad5874d08a70dc59dcdff5206cbac376b608c8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731597300,
      "headline": "2 Dividend Stocks to Buy Hand Over Fist in November",
      "id": 131358417,
      "image": "https://g.foolcdn.com/editorial/images/797409/pharmacist-talking-to-patient.jpg",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "These companies have solid businesses and excellent dividend growth track records.",
      "url": "https://finnhub.io/api/news?id=2f826d3cfb75dfab1f1d576691ad5874d08a70dc59dcdff5206cbac376b608c8"
    }
  },
  {
    "ts": null,
    "headline": "AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations",
    "summary": "AbbVie (NYSE: ABBV) today announced 20 winners of the inaugural AbbVie Migraine Career Catalyst Award™ contest, a first-of-its-kind contest designed to support the career aspirations of people living with migraine. The winning entries were selected from short essay, video, and audio clip submissions highlighting entrants' experiences living with migraine, their career aspirations, and how this award could help support their future success.",
    "url": "https://finnhub.io/api/news?id=2c93289ac30ecf7986e12eac23115b58d3c09c57aae3903aa9ef8b6181c4a95c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731590100,
      "headline": "AbbVie Awards 20 Individuals Living With Migraine To Support Career Aspirations",
      "id": 131347915,
      "image": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
      "related": "ABBV",
      "source": "Yahoo",
      "summary": "AbbVie (NYSE: ABBV) today announced 20 winners of the inaugural AbbVie Migraine Career Catalyst Award™ contest, a first-of-its-kind contest designed to support the career aspirations of people living with migraine. The winning entries were selected from short essay, video, and audio clip submissions highlighting entrants' experiences living with migraine, their career aspirations, and how this award could help support their future success.",
      "url": "https://finnhub.io/api/news?id=2c93289ac30ecf7986e12eac23115b58d3c09c57aae3903aa9ef8b6181c4a95c"
    }
  },
  {
    "ts": null,
    "headline": "Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects",
    "summary": "Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ALDX stock a buy.",
    "url": "https://finnhub.io/api/news?id=3cf0855c027f4ae557c7a5afff896629d34ee9e7a403862a89e7b91311581416",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1731562276,
      "headline": "Aldeyra's FDA Resubmission And AbbVie Option Revitalize Reproxalap's Prospects",
      "id": 131344453,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1823932204/image_1823932204.jpg?io=getty-c-w1536",
      "related": "ABBV",
      "source": "SeekingAlpha",
      "summary": "Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ALDX stock a buy.",
      "url": "https://finnhub.io/api/news?id=3cf0855c027f4ae557c7a5afff896629d34ee9e7a403862a89e7b91311581416"
    }
  }
]